key: cord-0713121-76degh7c
authors: Hatzl, Stefan; Reisinger, Alexander C.; Posch, Florian; Prattes, Juergen; Stradner, Martin; Pilz, Stefan; Eller, Philipp; Schoerghuber, Michael; Toller, Wolfgang; Gorkiewicz, Gregor; Metnitz, Philipp; Rief, Martin; Prüller, Florian; Rosenkranz, Alexander R.; Valentin, Thomas; Krause, Robert; Hoenigl, Martin; Schilcher, Gernot
title: Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study
date: 2021-09-15
journal: Crit Care
DOI: 10.1186/s13054-021-03753-9
sha: 44d46eab0c4cb815a9d46817ff3a8a2d5ebfac91
doc_id: 713121
cord_uid: 76degh7c

BACKGROUND: Coronavirus disease 19 (COVID-19)-associated pulmonary aspergillosis (CAPA) emerged as important fungal complications in patients with COVID-19-associated severe acute respiratory failure (ARF). Whether mould active antifungal prophylaxis (MAFP) can prevent CAPA remains elusive so far. METHODS: In this observational study, we included all consecutive patients admitted to intensive care units with COVID-19-associated ARF between September 1, 2020, and May 1, 2021. We compared patients with versus without antifungal prophylaxis with respect to CAPA incidence (primary outcome) and mortality (secondary outcome). Propensity score adjustment was performed to account for any imbalances in baseline characteristics. CAPA cases were classified according to European Confederation of Medical Mycology (ECMM)/International Society of Human and Animal Mycoses (ISHAM) consensus criteria. RESULTS: We included 132 patients, of whom 75 (57%) received antifungal prophylaxis (98% posaconazole). Ten CAPA cases were diagnosed, after a median of 6 days following ICU admission. Of those, 9 CAPA cases were recorded in the non-prophylaxis group and one in the prophylaxis group, respectively. However, no difference in 30-day ICU mortality could be observed. Thirty-day CAPA incidence estimates were 1.4% (95% CI 0.2–9.7) in the MAFP group and 17.5% (95% CI 9.6–31.4) in the group without MAFP (p = 0.002). The respective subdistributional hazard ratio (sHR) for CAPA incidence comparing the MAFP versus no MAFP group was of 0.08 (95% CI 0.01–0.63; p = 0.017). CONCLUSION: In ICU patients with COVID-19 ARF, antifungal prophylaxis was associated with significantly reduced CAPA incidence, but this did not translate into improved survival. Randomized controlled trials are warranted to evaluate the efficacy and safety of MAFP with respect to CAPA incidence and clinical outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03753-9.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19)-associated acute respiratory failure contributes to a highly permissive inflammatory environment. This in turn favours fungal pathogenesis due to the release of danger-associated molecular patterns and collateral effects of host Open Access *Correspondence: robert.krause@medunigraz.at † Stefan Hatzl, Alexander C. Reisinger, Martin Hoenigl and Gernot Schilcher contributed equally to this paper. 4 Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria Full list of author information is available at the end of the article recognition pathways required for the activation of antiviral immunity [1] . In this context, COVID-19-associated pulmonary aspergillosis (CAPA) has been emerging as an important fungal complication of COVID-19 [1] , affecting an average of 3.1% (range 0.7-7.7%) [2] [3] [4] [5] of patients hospitalized with COVID- 19, 8 .9% (range 2.5-39%) of patients admitted to the intensive care unit (ICU) [3, [6] [7] [8] [9] [10] [11] , and an average of 20.1% (range 3.2-38%) of those requiring invasive ventilation [6, 7, [12] [13] [14] .

Diagnosis of CAPA is challenging in patients with COVID-19-associated ARDS, as clinical picture and radiological findings of CAPA resemble those of severe COVID-19 [15, 16] , and blood tests lack sensitivity due to the primarily airway invasive growth of Aspergillus in non-neutropenic patients [15] [16] [17] . Testing of bronchoalveolar lavage (BAL) with fungal culture, galactomannan (GM), Aspergillus polymerase chain reaction (PCR), or the Aspergillus GM lateral flow assay (LFA) is therefore preferred [18, 19] , but due to the presumed risk of COVID-19 transmission through bronchoscopies, sampling of the primary infection site is still not performed consistently across ICUs.

The high prevalence rates of CAPA in critically ill patients requiring invasive ventilation together with the difficulties in diagnosis and the devastating overall mortality rates of over 50% [2-4, 6, 9-12, 14, 15, 20, 21] could justify clinical trials evaluating antifungal prophylaxis in COVID-19 patients with acute respiratory failure. One retrospective single-centre case series from Belgium has reported the successful use of prophylaxis in terms of CAPA case reduction with inhaled liposomal Amphotericin B in a cohort of ICU patients with severe COVID-19 [6] ; however, studies evaluating systemic antifungal prophylaxis are lacking.

The objective of this observational single-centre study was to evaluate the effectiveness of mould-active antifungal prophylaxis in preventing CAPA in critical care patients with COVID-19-associated acute respiratory failure. Secondary objectives included the evaluation of a potential survival benefit associated with antifungal prophylaxis as well as the impact of CAPA on overall survival.

We performed an observational study, enrolling all consecutive adult SARS-CoV-2 polymerase chain reaction (SARS-CoV-2 PCR) positive patients to our ICUs at the Department of Internal Medicine, Medical University of Graz, Austria (later referred to as ICU 1), or the Department of Anaesthesiology, Medical University of Graz, Austria (later referred to as ICU 2), between September 1, 2020, and May 1, 2021.

All patient data were uniformly collected as described previously [22, 23] . Therefore, laboratory, clinical and radiology data were extracted from our in-house electronic healthcare database system and inserted in a predefined electronic case report form (eCRF) using REDCap electronic data capture [24, 25] . For classification of CAPA, the 2020 European Confederation of Medical Mycology (ECMM)/International Society of Human and Animal Mycoses (ISHAM) consensus criteria were used [16] . According to these criteria, patients were categorized as either proven, probable or possible pulmonary and/or tracheobronchial CAPA, or no evidence for CAPA. In those receiving antifungal prophylaxis, CAPA cases were further classified according to the ECMM/ MSG definitions for breakthrough infections [26] . To reduce confirmation bias, CAPA classification was made by two infectious disease specialists who were blinded against the baseline characteristics and the administration of mould active antifungal prophylaxis.

Data analysis was performed after exclusion of fourteen patients who did not meet the predefined inclusion criteria or met a predefined exclusion criterion after initial screening (Fig. 1) .

The research project was approved by the local institutional review board (EC #32-296 ex 19/20).

Assignment to antifungal prophylaxis was informed by our in-house recommendation, which recommended antifungal prophylaxis with posaconazole or a similar mould active antifungal drug for every COVID-19 patient with acute respiratory failure admitted to the ICU. This recommendation was based on our experience with COVID-19-associated mould infections occurring before September 2020 [16, 27, 28] and on frequent fungal resistance testing within our centre which revealed no case of azol resistance in Aspergillus spp. to date. This recommendation was first implemented at ICU 1 and later at ICU 2. However, the decision of administration of mould active antifungal prophylaxis largely relays on the treating intensivist allowing us to compare outcomes of patients with and without antifungal prophylaxis who were otherwise treated according to same medical standards. Treated patients and control patients were distributed among both intensive care units.

All statistical analyses were performed using Stata (Windows version 16.1; Stata Corp., Houston, TX, USA) and R 4.0.5 (https:// www.r-proje ct. org/) and followed an a priori specified analysis plan (Additional file 1: Figure S1 ). The distribution of baseline variables between the antifungal prophylaxis and no antifungal prophylaxis group was evaluated using rank-sum tests, χ 2 -tests, and Fisher's exact tests, as appropriate. The magnitude of these differences was quantified with standardized mean differences (SMDs), and SMDs ≥ 0.31 were considered indicative of a potentially relevant magnitude of difference. To account for differences in covariates between the groups with and without antifungal prophylaxis, we used propensity score analyses. We obtained the propensity score e from a multivariable logistic regression model with antifungal prophylaxis group as the outcome variable. For this model, we pre-specified a fixed number of maximum 10 predictor variables, in order not to have less than 3 events per predictor variable. In detail, the model was developed by initially including all variables with a p for difference between the two groups of ≤ 0.16 and/or a SMD ≥ 0.31. The propensity score e was then transformed into an inverse-probability-of-treatment-weight (IPTW) according to the average treatment effect principle, i.e. = (AntifungalProphylaxis)

where antifungal prophylaxis denotes the treatment assignment [29] . For balance diagnostics, we then re-estimated SMDs and p-values for difference between the two treatment groups with the IPTW-weighted data [30, 31] . For this propensity score model, missing data of ten variables (body mass index, paO 2 /FiO 2 , positive end expiratory pressure, lactate, interleukin 6, C-reactive protein, ferritin, high sensitive troponin T, D-Dimer, absolute lymphocyte count) were imputed using a chained equations algorithm [32] . Between-group tests for differences were re-performed after weighting with the IPTW.

Sensitivity analyses included a trimmed IPTW (i.e. excluding patients with an IPTW ≤ the 1st and ≥ the 99th percentile of its distribution).

The primary outcome of the study, occurrence of CAPA within 30-days of ICU admission, was defined as the time interval from ICU admission to the time point when the first positive sample for CAPA was obtained or the censoring date which was set the latest at 30 days from ICU admission. Survival time was inflated by one day in patients who died at the day of ICU admission (n = 2). The secondary outcome of the study, 30-day ICU overall survival (OS), was defined as the time interval from ICU admission to death-from-any-cause or the censoring date when being still alive 30 days after ICU admission.

In addition, we also analysed 90-day ICU overall survival to evaluate long-term ICU survival.

Univariable unweighted and IPTW-weighted Cox proportional hazards models and Fine and Gray proportional sub-distribution hazards models were fitted for analysing the association between antifungal prophylaxis and timeto-event end points, respectively.

Univariable unweighted and IPTW-weighted risks of development of CAPA and death-from-any-cause were analysed with competing risk cumulative incidence estimators, Gray's tests, and Fine and Gray proportional sub-distribution hazards models, respectively. Deathfrom-any-cause was considered as competing event of interest in the analyses of CAPA development risk [33] .To eliminate immortal time bias in the analysis of the association of CAPA with ICU overall survival, the occurrence of CAPA was modelled as a time-dependent variable within Cox models. The association of CAPA with ICU survival was defined as co-secondary outcome. This was achieved by partitioning the follow-up time of patients who developed CAPA into times before and after CAPA diagnosis. For visual display of the association between CAPA and ICU overall survival outcomes, we performed a landmark analysis after 14 days of ICU admission. This landmark was chosen because most CAPA diagnosis happened in the first 2 weeks after ICU admission.

The full dataset and the main analysis code are available upon request by the first author.

In all analyses p values < 0.05 were considered statistically significant.

Over the study period, 132 patients were admitted to the ICUs due to COVID-19-associated acute respiratory failure and therefore included in the final analysis ( Fig. 1 ). Of those, 75 (57%) patients received mould active antifungal prophylaxis within the first 48 h after ICU admission according to our local standard, while the remaining 57 (43%) did not. At the time of ICU admission, the median age of patients was 65 years [25th-75th percentile: 55-75], and 48 (36%) patients were female. The investigated population had a median of two coexisting conditions [1] [2] [3] [4] and a median time from SARS-CoV-2 PCR positivity to ICU admission of 3 days [0-6]. All patients included in this study showed an oxygen saturation of less than 88% while breathing ambient air prior to ICU admission and were classified as acute respiratory failure. Most patients exhibited severe acute respiratory failure as displayed by a median paO2/FiO2 ratio (Horowitz Index) of 95 [25th-75th percentile 75-146]. Seventy-two patients (56%) required invasive ventilation including veno-venous extracorporeal membrane oxygenation (vvECMO) (n = 13) and/or endotracheal intubation (n = 59). All patients in this study received systemic glucocorticoids as supportive treatment. Remdesivir was administered in 33 (40%) patients, convalescent plasma was given to 50 (38%) patients, whereas only one patient received tocilizumab (Table 1) . During the first 30-days after ICU admission, we observed 10 CAPA cases, corresponding to 1-, 15-, and 30-day CAPA incidence of 0.8% (95% CI 0.1-5.2), 8.5% (4.6-15.2), and 8.5% (4.6-15.2), respectively, in the complete cohort (Additional file 2: Figure S2 ).

Out of 75 patients receiving antifungal prophylaxis, 73 (98%) received standard dosage of intravenous posaconazole as mould active antifungal prophylaxis as recommended by our in-house protocol. One patient (1%) received intravenous isavuconazole due to impaired tolerance against posaconazole. One patient (1%) received caspofungin due to a suspected prior anaphylactic reaction against azoles. All patients within the prophylaxis group were started on antifungal prophylaxis within 48-h after ICU admission (Table 1) . At both ICU´s routine serum-galactomannan and bronchoalveolar lavage-galactomannan testing was performed, and no differences in the frequencies of GM testing was observed between the prophylaxis and no prophylaxis group excluding any observation bias (Additional file 3: Table S1 ).

As outlined in Table 1 , patients in the prophylaxis group had a lower body mass index, higher rates of chronic kidney disease, higher serum levels of creatinine and haemodialysis, lower rates of coronary artery disease, a higher proportion of immunosuppression, lower sequential organ failure score (SOFA), less frequencies in mask oxygen supply, lower levels of D-Dimer at ICU admission and received more frequently remdesivir as treatment for COVID-19 (Additional file 4: Figure S3 ). These imbalances between the treatment groups might display a non-random assignment bias. We pre-specified a propensity score model including a maximum of 10 variable; however, only 9 met the criteria of p ≤ 0.16 and/ or SMD ≥ 0.31. Therefore, we predicted a propensity score based on a 9-variable multivariable logistic regression model (Additional file 5: Table S2 ) to control for the between group differences. The propensity score covered the whole probability range (Additional file 6: Figure  S4A ) and was then transformed into the IPTW (Additional file 6: Figure S4B ). The propensity score was able to eliminate all difference between the treatment groups after re-weighting of the data (Table 1 , Additional file 4: Figure S3 ) which allowed us to correct for a potential non-random assignment bias and provide more reliable results. Moreover, the trimmed IPTW showed the same potential in reducing the between group differences showing a high reliability of the computed propensity score (data not shown).

During the first 30-days after ICU admission, we observed 10 CAPA cases (9 probable and 1 possible CAPA cases), corresponding to 1-, 15-, and 30-day CAPA incidence of 0.8% (95% CI 0. The discrepancy between missing variable regarding pO 2 /FiO 2 and ARDS classification inspired by the Berlin 2015 classification arises from missing exact pO 2 /FiO 2 values; however, ARDS was classified Abbreviations: BMI body mass index; ICU intensive care unit; COPD chronic obstructive pulmonary disease; SOFA sequential organ failure assessment; PEEP positive end expiratory pressure; vvECMO veno-venous extracorporeal membrane oxygenation, NIV non-invasive ventilation, HFNC high flow nasal cannula; IL-6 interleukin 6; CRP C-reactive protein; hs-TnT high sensitive troponin T, SARS-CoV2 severe acute respiratory syndrome corona virus 2; CAPA coronavirus disease-associated pulmonary aspergillosis $ documented coronary heart disease either by specific coronary imaging or coronary angiography † comprises immunosuppressive medication (low dose of glucocorticoids are excluded) as well as diseases with severe immunosuppression § Glucocorticoids included low-dose dexamethasone or equivalent doses of other glucocorticoids the ECMM/ISHAM consensus. In detail, in the nonprophylaxis group 3 patients received isavuconazole and 6 received posaconazole, the patient in the prophylaxis group developing a breakthrough infection was switched to isavuconazole. Detailed characteristics of the CAPA patients are summarized in Additional file 7: Table S3 . Of the 10 CAPA cases, 9 occurred in patients not receiving anti-mould prophylaxis, while one occurred in the anti-mould prophylaxis group (one time serum GM positivity as only mycological criterion in that patient, while BAL GM was negative). With the unadjusted competing risk analysis, the 30-day CAPA incidence estimates were 17.5% (95% CI 9.6-31.4) in the non-antifungal prophylaxis group and 1.4% (95% CI 0.2-9.7) in those receiving anti-mould prophylaxis (Gray´s test p = 0.002, Fig. 2A ). In the Fine and Gray´s model, this corresponded to a sub-distributional hazard Ratio (SHR) of 0.08 (95% CI 0.01-0.63, p = 0.017) in the group with versus without administration of mould active antifungal prophylaxis.

In addition, we performed an analysis using the reweighted data with the generated IPTW. After adjustment, the 30-day CAPA incidence estimates were 15.8% in the non-antifungal prophylaxis group and 1.1% in the mould active antifungal prophylaxis group (Gray´s test p = 0.001, Fig. 2B ). In the Fine and Gray´s model, this corresponded to a SHR of 0.07 (95% CI 0.01-0.57, p = 0.013) for administration of mould active antifungal prophylaxis.

Further univariable analyses of 30-day-CAPA identified higher positive end-expiratory pressure (HR per 1 cmH 2 O increase = 1.04, 95% CI 1.02-1.07, p = 0.001), endotracheal intubation (HR 4.89, 95% CI 1.03-23.03, p = 0.045), and decreased absolute lymphocyte counts (HR per 1 G/l increase = 0.30, 95% CI 0.10-0.93, p = 0.037) as factors associated with CAPA (Additional file 8: Table S4 ). To determine the independent prognostic value of mould active antifungal prophylaxis for 30-day-CAPA development, multivariable analyses including all univariable predictors were performed. Here, the prognostic association prevailed. (Additional file 9: Table S5 ).

Within 30 days of ICU admission, 48 deaths were observed, corresponding to 1-, 15-, and 30-day ICU survival estimates of 96% (95% CI 91-98), 78% (70-84), and 63% (54-71), respectively, in the whole cohort (Additional file 2: Fig. S2 ).

In the time to event analysis, patients receiving antifungal prophylaxis experienced no improvement of 30-day ICU survival outcomes: 1-, 15-and 30-day ICU survival rates were 98.6% (95% CI 90.1-99. the treatment groups (log-rank p = 0.955) (Fig. 3A) . To account for the non-random assignment bias, we also re-weighted this data for the IPTW. However, the reweighted analysis also showed no differences in 30-day ICU survival between patients receiving antifungal prophylaxis and those who did not (log-rank p = 0.905) (Fig. 3B ). To investigate a potential effect of mould-active antifungal prophylaxis on long-term ICU survival, we repeated the time-to-event analysis for 90-day ICU survival. Interestingly, no difference between both groups could be observed regarding this co-secondary endpoint (Additional file 10: Fig. S5) .

Using a univariable time-to-event regression analysis treating development of CAPA as dependent variable, we also evaluated impact of CAPA on 90-day ICU survival as co-secondary outcome for long-term survival. Patients who developed CAPA during their ICU stay displayed worse outcomes regarding 90-day ICU mortality (HR 2.30, 95% CI 1.08-4.91, p = 0.031). These findings prevailed in multivariable regression analyses adjusting for prognostic co-variates, such as age, SOFA, creatinine, number of comorbidities, body-mass-index, immunosuppression, and supportive treatment with convalescent plasma as previously described (Additional file 11: Table S6 ). In a landmark analysis after 14 days, 90-day ICU survival estimates were 63.8% and 16.7% in patients in patients with and without CAPA during their ICU stay (Mantel-Byar p = 0.026, Fig. 4 ).

We observed that mould-active antifungal prophylaxis for patients with COVID-19-associated acute respiratory failure admitted to the ICU was highly effective in preventing CAPA. In patients without antifungal prophylaxis, CAPA was diagnosed in 17.5% versus only in 1.4% of those receiving prophylaxis, representing a reduction in relative risk for development of CAPA of 92% in the prophylaxis group and a number needed to receive prophylaxis of 7 to prevent one CAPA case. These results outline the efficacy of prophylaxis with posaconazole. While CAPA was associated with significantly higher mortality, antifungal prophylaxis did not have a significant impact on overall survival.

In our study, mould active antifungal prophylaxis resulted in a > 90% reduction of CAPA, outlining the After adjusting for differences in baseline characteristics, the positive effect of mould active antifungal prophylaxis was even stronger. The vast majority of patients in our study received posaconazole prophylaxis, the current gold standard for antifungal prophylaxis in patients with haematological malignancies [34, 35] . Posaconazole and particularly its newer tablet and intravenous formulations have several advantages compared to other drugs that are used for prophylaxis, starting with favourable pharmacokinetics, long half live and high intracellular concentrations [36] . Voriconazole and isavuconazole are predominantly metabolized by the CYP enzyme system resulting in higher rates of drug-drug interactions, when compared to posaconazole which is metabolized predominantly through the uridine diphosphate-glucuronyltransferase enzyme pathways [37] [38] [39] . Voriconazole is in fact among the drugs most frequently associated with major drug-drug interactions in the ICU setting [40] , and may also show interactions with remdesivir which also is a substrate for CYP3A4, although its metabolism is primarily mediated by hydrolase activity [41] . Administration of intravenous liposomal Amphotericin B is complicated by the fact that SARS-CoV-2 has shown renal tropism and has been described as a frequent cause of acute kidney injury [42] . Inhaled amphotericin B may be an alternative for prophylaxis of CAPA but lacks regulatory approval in this application and has been associated with severe adverse events [43] . Therefore, posaconazole seems for now an appropriate choice for CAPA prophylaxis, although isavuconazole may be an alternative. New antifungal classes currently under development, namely fosmanogepix and olorofim, which show equal efficacy with minimal drug-drug interactions and toxicity in current phase IIb studies may become options/alternatives soon.

Using antimould prophylaxis for prevention of CAPA is attractive, because CAPA has been associated with high mortality rates [2-4, 12, 15] , which was confirmed in our study where patients who developed CAPA during their ICU stay displayed worse outcomes with a more than twofold higher mortality compared to patients without CAPA. Given that patients who succumb very early after ICU admission are no longer able to develop CAPAand most diagnoses occurred within 14 days after ICU admission in our cohort (median time to diagnosis 6 days after ICU admission)-we performed a landmark analysis from this time point and found that survival estimates were 64% in patients without CAPA compared to 17% in those diagnosed with CAPA. While early treatment may reduce mortality [2] , early diagnosis of CAPA is challenging because clinical presentation and imaging findings of COVID-19 and CAPA may overlap (fever, shortness of breath, cough; unspecific infiltrates and consolidations, halo sign), and serum galactomannan has a low sensitivity [1, 15] . While prolonged neutropenia, stem-cell transplantation, immunosuppression, underlying lung disease, or systemic corticosteroids have been described as risk factors for development of CAPA [1] , none of those is a strong predictor of CAPA, which may very well also develop in patients without any other risk factors than COVID-19-associated acute respiratory failure [1] .

Pulmonary aspergillosis may also complicate acute respiratory failure caused by other viral infections, among those with severe influenza where we have recently observed three cases of pulmonary aspergillosis in our centre [19] .

In a recent study on anti-mould prophylaxis to prevent influenza-associated aspergillosis [44] , posaconazole did not show significant benefit due to the fact that patients developed invasive aspergillosis mostly within 48 h of ICU admission (i.e. before posaconazole reaches its steady state [45] ). In contrast, CAPA has been shown before to develop mostly > 5 days after ICU admission, by which time steadystate posaconazole levels are usually reached [15, 46, 47] , making it a better target for antifungal prophylaxis.

Importantly, the prevalence of CAPA has been shown to vary between centres. The prevalence of 17.5% observed in our cohort not receiving anti-mould prophylaxis was higher than the median 8.9% reported previously for COVID-19 patients admitted to ICU [3, 6-11, 20, 48, 49] , but has been lower than the median 20.1% reported in other studied for COVID-19 patients requiring invasive ventilation [4, 6, 7, [12] [13] [14] . Whether or not the > 90% efficacy in reducing CAPA shown in our study will justify the broad use of antimould prophylaxis in other centres will mainly depend on local prevalence rates of CAPA. Targeted use of prophylaxis in certain groups of patients at higher risk may also be an option for some centres.

Our study has several limitations including those patients were not randomized to receive mould active antifungal prophylaxis, and cases and controls were enrolled-in part-at different ICUs. However, we found similar baseline characteristics in patient with or without mould active antifungal prophylaxis, and additionally adjusted for any imbalances using a propensity score and IPTW weighted analysis. Also, this is a single-centre study and although the observed prevalence in our centre was within the range reported before, the reported range is wide and prevalence of CAPA observed in our centre may not translate to other centres.

In conclusion, this is the first study evaluating efficacy of mould active antifungal prophylaxis in ICU patients suffering from acute respiratory failure due to COVID-19. We were able to show in our cohort that antifungal

COVID-19 Associated Pulmonary Aspergillosis (CAPA)-from immunology to treatment

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study

COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan

COVID-19 Associated Pulmonary Aspergillosis

Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia

COVID-19-associated invasive pulmonary aspergillosis

Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients

Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Diseases

COVID-19 Associated Pulmonary Aspergillosis

Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity

Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19

Is the COVID-19 pandemic a good time to include aspergillus molecular detection to categorize aspergillosis in ICU patients? A monocentric experience

Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19)

COVID-19-Associated Pulmonary Aspergillosis

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

Aspergillus fumigatus and aspergillosis: from basics to clinics

Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches

Performance of the bronchoalveolar lavage fluid aspergillus galactomannan lateral flow assay with cube reader for diagnosis of invasive pulmonary aspergillosis: a Multicenter Cohort Study

Risk factors for invasive pulmonary aspergillosis in critically ill patients with coronavirus disease 2019-induced acute respiratory distress syndrome

Aspergillosis complicating severe coronavirus disease

Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study

Response to "COVID-19 in persons with haematological cancers

The RED-Cap consortium: building an international community of software platform partners

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology

Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically Ill COVID-19 patient with underlying hematological malignancy

Invasive pulmonary aspergillosis complicating COVID-19 in the ICU -A case report

An introduction to propensity score methods for reducing the effects of confounding in observational studies

Bootstrap methods for developing predictive models

Avoiding bias due to perfect prediction in multiple imputation of incomplete categorical variables

Multiple imputation using chained equations: Issues and guidance for practice

A proportional hazards model for the subdistribution of a competing risk

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?

Population pharmacokinetics of voriconazole in adults

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH

Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists

Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases

Multiorgan and Renal Tropism of SARS-CoV-2

Anti-aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis

Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proofof-concept trial

Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology

Influenza-and COVID-19-associated pulmonary aspergillosis: are the pictures different?

Posaconazole plasma concentrations on days three to five predict steady-state levels

Clinical features and shortterm outcomes of 221 patients with COVID-19 in Wuhan

Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

prophylaxis was able to prevent CAPA. The occurrence of CAPA was found to be associated with poor outcomes.

The online version contains supplementary material available at https:// doi. org/ 10. 1186/ s13054-021-03753-9.